Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Dec;97(49):e13093.
doi: 10.1097/MD.0000000000013093.

Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report

Affiliations
Case Reports

Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report

Dan Yang et al. Medicine (Baltimore). 2018 Dec.

Abstract

Rationale: Diffuse large B-cell lymphoma (DLBCL) is a neoplasm of large B lymphoid cells that exhibits diffuse growth patterns. Patients may present with nodal and/or extranodal disease. The most common extranodal site is the gastrointestinal tract, while skin is less common.

Patient concerns: We report a case of secondary skin involvement of an original gastric DLBCL, which has achieved a complete response after treatment with chidamide.

Diagnoses: Initially, the diagnosis of gastric DLBCL is clear, and this patient responded well to systemic chemotherapy (rituximab + cyclophosphamide + epirubicin + vincristine + prednisone) after 8 cycles. Thirty months later, some rapidly enlarging skin nodules on his arm were found. These skin nodules were diagnosed as secondary cutaneous DLBCL based on the clinical features, positron emission tomography-computed tomography, and histomorphologic and immunohistochemical expression.

Interventions: Steroids, interferon-α, and radiation had little therapeutic effect. We treated the patient with chidamide at 30 mg twice per week in combination with dexamethasone.

Outcomes: The skin nodules regressed 3 weeks later. During the 1-year follow-up period, the patient is still in treatment with chidamide without adverse reactions.

Lessons: To the best of our knowledge, this is the first case of secondary skin DLBCL reported to exhibit a complete response to chidamide, which provides a novel therapeutic strategy for secondary skin DLBCL. However, more cases are still needed to further validate its efficacy.

PubMed Disclaimer

Conflict of interest statement

Authors declare no competing financial interests.

Figures

Figure 1
Figure 1
Gastroscopic biopsies and immunohistochemical staining. (A) A 3 × 5 cm ulcer with purulent secretion was found at the bottom of the stomach. (B) Stomach biopsy revealed diffuse infiltration by large lymphoid cells (hematoxylin–eosin, ×40). (C) CD20 (×200). (D) MUM1 (×200). (E) Ki-67 (×200).
Figure 2
Figure 2
Immunohistochemical analysis of skin biopsy (July 29, 2014). (A) Skin biopsy revealed diffuse infiltration by large lymphoid cells in the dermis and subcutaneous tissue (hematoxylin–eosin, ×200). (B) CD20 (×200). (C) BCL-2 (×200). (D) Ki-67 (×200).
Figure 3
Figure 3
F-18 fluorodeoxyglucose (FDG) PET-CT and immunohistochemical analysis of skin biopsy (July 4, 2017). (A) A PET-CT scan revealed a slight uptake of FDG in the skin of his left limb (black and white arrow). (B) Skin biopsy revealed diffuse infiltration by large lymphoid cells in the dermis and subcutaneous tissue (HE, ×200). (C) CD20 (×200). (D) BCL-2 (×200). (E) Ki-67 (×200). PET-CT = positron emission tomography-computed tomography.
Figure 4
Figure 4
Clinical features of buttocks. (A) Solitary red subcutaneous nodules on the buttocks before chidamide therapy (August 1, 2017). (B) Subcutaneous nodules disappeared on August 29, 2017 after chidamide therapy.

Similar articles

Cited by

References

    1. The Non-Hodgkin's Lymphoma Classification Project A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909–18. - PubMed
    1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780–95. - PubMed
    1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–92. - PubMed
    1. Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the surveillance, epidemiology, and end results database. Am J Hematol 2014;89:310–4. - PubMed
    1. Lee WJ, Won KH, Won CH, et al. Secondary cutaneous diffuse large B-cell lymphoma has a higher international prognostic index score and worse prognosis than diffuse large B-cell lymphoma, leg type. Acta Derm Venereol 2016;96:245–50. - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts